4-氨基-5-氟-1-[(2R,5S)-5-(羟基甲基)四氢呋喃-2-基]嘧啶-2-酮 | 107036-62-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘧啶核苷
• 中文名称: 4-氨基-5-氟-1-[(2R,5S)-5-(羟基甲基)四氢呋喃-2-基]嘧啶-2-酮
• 英文名称: 5-fluoro-2',3'-dideoxycytidine
• 英文别名: β-D-(5-fluoro)-2',3'-dideoxycytidine；β-D-2',3'-dideoxy-5-fluorocytidine；2',3'-dideoxy-β-D-5-fluorocytidine；2',3'-dideoxy-β-L-5-fluorocytidine；2',3'-dideoxy-5-fluorocytidine；4-amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
• CAS: 107036-62-4
• 化学式: C₉H₁₂FN₃O₃
• 分子量: 229.211
• InChiKey: QBEIABZPRBJOFU-CAHLUQPWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  88.2
• 氢给体数：
  2
• 氢受体数：
  4

制备方法与用途

2',3'-二脱氧-5-氟胞苷是一种嘌呤核苷类似物，具有广泛抗肿瘤活性，尤其针对惰性淋巴系统恶性肿瘤。其抗癌机制主要依赖于抑制DNA合成和诱导细胞凋亡等过程。

反应信息

• 作为产物：
  描述：

  5-氟-2'-脱氧脲核苷 在 劳森试剂 、 吡啶 、 偶氮二异丁腈 、 氨 、 三正丁基氢锡 作用下， 以 氯仿 、 甲苯 、 苯 为溶剂， 65.0~138.0 ℃ 、1.72 MPa 条件下， 反应 28.5h， 生成 4-氨基-5-氟-1-[(2R,5S)-5-(羟基甲基)四氢呋喃-2-基]嘧啶-2-酮
  参考文献：
  名称：

  Potential anti-AIDS drugs. 2',3'-Dideoxycytidine analogs

  摘要：

  5-Substituted 2',3'-dideoxycytidine analogues have been synthesized and evaluated in vitro for their capabilities to protect T4+ lymphocytes from the cytopathic effects of the HTLV-III/LAV (HIV) virus, the causative agent of acquired immunodeficiency syndrome (AIDS). These analogues were designed to be more lipophilic than 2',3'-dideoxycytidine (ddC) in order to enhance central nervous system penetration. Earlier reports had shown that ddC is a potent protective agent. When ddC is substituted at the 5-position with either methyl or bromo substituents, activity is completely abolished. However, when the substitution is fluoro (5-F-ddC), both activity and potency are retained. 2',3'-Dideoxy-5-azacytidine is also protective but more toxic than ddC or 5-F-ddC. In a different approach, an attempt was made to utilize ddCMP, ddTMP, and ddAMP as preformed nucleotides in order to circumvent the generally low level of phosphorylation achieved with dideoxynucleosides which function as relatively poor substrates for the cellular kinases. Only ddAMP is as active as its nucleoside precursor. Because ddAMP is not more active than ddA at low concentrations, it is possible that the active agent is ddA which is generated from ddAMP prior to cell entry.

  DOI：

  10.1021/jm00388a020

文献信息

• NMR studies of pyrimidinic nucleosides derived from 2,3-dideoxy-<scp>d</scp> -ribose with inhibitory activity on LINE-1 mobility
  作者：Guillermo Banuelos-Sanchez、Francisco Franco-Montalban、Juan A. Tamayo

  DOI：10.1002/mrc.4942

  日期：2020.1

  their minimal NMR data described in Reference 10. Here in this work, we describe the complete H and C signals assignment of these 36 nucleosides having pyrimidine, 5‐ aza‐pyrimidine, and 6‐aza‐pyrimidine bases with 2,3‐ dideoxy‐D‐ribose, both 5′‐O‐protected and unprotected (1–36), by means of its 2‐D spectra as well as 1D‐NOE experiments. In addition, and as previously reported by Okabe and Lin, we

  嘧啶核苷类似物具有很高的药理学价值。它们显示出非常有用的抗 VIH、乙型肝炎病毒和抗癌活性的抗病毒活性，目前用于治疗这些疾病。鉴于其重要性，许多科学家修改了这些核苷类似物的结构，以寻求改善其特性、靶向特异性、功效并降低其毒性。由于这项研究，一些类似物被描述为具有改进的特性，其中包括源自 2,3-双脱氧-D-核糖的核苷，如齐多夫定 (AZT)、去羟肌苷 (ddI) 和扎西他滨 (ddC)。许多研究人员还研究了这些化合物的核磁共振谱。特别是，他们描述了异头构型对化合物中的 H 和 C NMR 信号的影响，例如，腺苷核苷或异核苷。作为我们抑制转座因子（如 LINE-1）研究的一部分，我们合成了（方案 1）18 种 2',3'-双脱氧核糖核苷性质的核苷类似物（化合物 1-18，图 1）及其相应的前体（化合物 19-36，图 2）和针对哺乳动物 LINE-1 逆转录转座的 1-18 检测，获得了非常
• Synthesis and Characterization of Specific Reverse Transcriptase Inhibitors for Mammalian LINE-1 Retrotransposons
  作者：Guillermo Banuelos-Sanchez、Laura Sanchez、Maria Benitez-Guijarro、Valentin Sanchez-Carnerero、Carmen Salvador-Palomeque、Pablo Tristan-Ramos、Meriem Benkaddour-Boumzaouad、Santiago Morell、Jose L. Garcia-Puche、Sara R. Heras、Francisco Franco-Montalban、Juan A. Tamayo、Jose L. Garcia-Perez

  DOI：10.1016/j.chembiol.2019.04.010

  日期：2019.8

  LINE-1-retroelements use different mechanisms for retrotransposition, although both involve the reverse transcription of an intermediate retroelement-derived RNA. Retrotransposon activity continues to effect the germline and somatic genomes, generating interindividual variability over evolution and potentially influencing cancer and brain physiology, respectively. However, relatively little is known about

  逆转座子是在哺乳动物基因组中扩增到惊人数量的一种可转座元件（TE），包括超过三分之一的人类和小鼠基因组。长时间散布的1类元素（LINE-1或L1）反转录转座子丰富，目前在人类和小鼠基因组中具有活跃的反转录元件。同样，两个基因组中都含有长末端重复序列（LTR）的逆转座子，尽管仅在小鼠中有活性。LTR和LINE-1-逆转录元件使用不同的逆转座子机制，尽管两者都涉及中间逆向元件衍生的RNA的逆转录。反转录转座子的活性继续影响种系和体细胞基因组，在进化过程中产生个体差异，并分别影响癌症和脑部生理。然而，关于逆转座的功能后果知之甚少。在这项研究中，我们已经合成和表征了针对哺乳动物LINE-1逆转座子的逆转录酶抑制剂，这可能有助于破译体内逆转座子的功能。
• Novel fluorophosphonate nucleotide derivatives
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0339161A1

  公开（公告）日：1989-11-02

  This invention relates to fluoromethylphosphonate derivatives of certain nucleosides, to methods for their preparation and to their use as antiviral and antitumoral agents.

  这项发明涉及某些核苷类化合物的氟甲基磷酸酯衍生物，涉及它们的制备方法以及它们作为抗病毒和抗肿瘤药物的用途。
• Novel phosphonic acid based prodrugs of PMEA and its analogues
  申请人：——

  公开号：US20030229225A1

  公开（公告）日：2003-12-11

  Prodrugs of Formula I, their uses, their intermediates, and their method of manufacture are described: 1 wherein: M and V are cis to one another and MPO 3 H 2 is a phosphonic acid selected from the group consisting of 9-(2-phosphonylmethoxyethyl)adenine, (R)-9-(2-phosphonylmethoxy propyl)adenine, 9-(2-phosphonylmethoxyethyl)guanine, 9-(2-phosphonylmethoxy ethyloxy)adenine, 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine, (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine, (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine, 9-(3-hydroxy-2-phosphonylmethoxypropyl)guanine, and (S)-9-(3-fluoro-2-phosphonyl methoxypropyl)adenine; V is selected from a group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-furanyl, 3-furanyl, 2-thienyl, and 3-thienyl, all optionally substituted with 1-3 substituents selected from a group consisting of F, Cl, Br, C1-C3 alkyl, CF 3 and OR 6 ; R6 is selected from the group consisting of C1-C3 alkyl, and CF 3 ; and pharmaceutically acceptable salts thereof.

  公式I的前药、它们的用途、它们的中间体以及它们的制造方法被描述：其中：M和V相对于彼此是顺式的，MPO3H2是从以下组中选择的膦酸，包括9-(2-膦甲氧基乙基)腺嘌呤，(R)-9-(2-膦甲氧基丙基)腺嘌呤，9-(2-膦甲氧基乙基)鸟嘌呤，9-(2-膦甲氧基乙氧基)腺嘌呤，9-(2-膦甲氧基乙基)-2,6-二氨基嘌呤，(S)-1-(3-羟基-2-膦甲氧基丙基)胞嘧啶，(S)-9-(3-羟基-2-膦甲氧基丙基)腺嘌呤，9-(3-羟基-2-膦甲氧基丙基)鸟嘌呤，以及(S)-9-(3-氟-2-膦甲氧基丙基)腺嘌呤；V从以下组中选择，包括苯基，2-吡啶基，3-吡啶基，4-吡啶基，2-呋喃基，3-呋喃基，2-噻吩基和3-噻吩基，所有这些基可选地被1-3个来自F、Cl、Br、C1-C3烷基、CF3和OR6的基替代；R6从C1-C3烷基和CF3的组中选择；以及其药学上可接受的盐。
• [EN] NUCLEOSIDE AND NUCLEOTIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES ET DE NUCLÉOTIDES
  申请人：ENANTA PHARM INC

  公开号：WO2016033164A1

  公开（公告）日：2016-03-03

  The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: (I) which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral/anti-proliferative compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral infection in a subject in need of such therapy with said compounds.

  本发明揭示了化合物(I)或其药学上可接受的盐，该化合物可抑制、预防或治疗异常细胞增殖和/或病毒感染，特别是HIV、HCV或HBV感染。因此，本发明的化合物干扰病毒的复制周期，也可用作抗病毒剂，或干扰宿主细胞的生化过程，也可用作抗增殖剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有病毒感染和/或细胞增殖的受试者。本发明还涉及通过给予包含本发明化合物的制药组合物来治疗受试者的病毒感染和/或细胞增殖的方法。本发明涉及上述新型抗病毒/抗增殖化合物，包括这些化合物的制药组合物，以及使用这些化合物治疗或预防受需要的受试者的病毒感染的方法。